Sangamo Therapeutics: Court Clears Bidding Procedures as Nasdaq Denies Continued Listing
SGMOQ has more than doubled off its 52-week low of $0.03 on light trading volume (0.3× avg).
Summary
Sangamo Therapeutics received court approval for bidding procedures in its Chapter 11 case, setting an August 4 bid deadline and August 20 sale hearing. Nasdaq also denied the company's appeal to continue its listing, finalizing its move to the OTCID Basic Market.
Key Events · Legal and Risk Events · SGMOQ
-
Bankruptcy Bidding Procedures Approved
The Delaware Bankruptcy Court approved bidding procedures for the sale of all or substantially all of Sangamo's assets, with a bid deadline of August 4, 2026, an auction (if needed) on August 10, 2026, and a sale hearing on August 20, 2026.
-
Nasdaq Delisting Denial Finalized
The Nasdaq Hearings Panel denied Sangamo's request to continue its listing on the Nasdaq Capital Market, following the company's failure to meet the minimum bid price requirement. The stock will be formally delisted and deregistered under Section 12(b).
-
Shareholder Recovery Uncertain
The asset sale process aims to maximize value for stakeholders, but common shareholders typically recover little to nothing in Chapter 11 cases, especially when the company's market cap is only $31 million and the stock trades at $0.0749.
-
Key Dates for Sale Process
Interested bidders must submit bids by August 4, 2026; an auction will be held on August 10 if multiple qualified bids are received; the court will consider approval of the winning bid(s) at a hearing on August 20, 2026.
Analysis · SGMOQ · Life Sciences
Already in Chapter 11 and trading on the OTCID Basic Market, Sangamo Therapeutics now has a court-approved roadmap to sell its assets, with a bid deadline of August 4, 2026, and a sale hearing on August 20, 2026. At the same time, Nasdaq has formally denied the company's appeal to remain listed, cementing its exit from the exchange. For shareholders, the asset sale process will determine whether any value remains after creditor claims are satisfied, while the Nasdaq delisting removes any remaining exchange liquidity and regulatory oversight.
At the time of this filing, SGMOQ was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $31M. The 52-week trading range was $0.03 to $0.77. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.